Outcomes of Pharmaceutical Care in Outpatients with Schizophrenia: A Randomized Controlled Trial
Article Sidebar
Main Article Content
Abstract
Objective: To compare the effect of the pharmaceutical care with that of usual care in outpatients with schizophrenia in terms of medication compliance, knowledge on disease and drug related problems. Method: Study design was a prospective, randomized controlled trial. The subjects were 69 outpatients with schizophrenia in Leelawadee clinic at Mahasarakham hospital. The researchers randomized the subjects into control group (n=37) which received usual care from the hospital and experimental group (n=32) which received patient education on knowledge about schizophrenia and medication, pharmaceutical care and telephone monitoring every week for 4 weeks (day 7, 14, 21, and 28 after receiving pharmaceutical care). Results: There were no significant differences in any baseline characteristic between control and experimental groups in terms of gender, age, availability of caregivers, medication compliance, knowledge on disease and medications, and drug-related problems, except for the forgetting to take medication which was higher in the control group over the experimental group. At the end of the study, no significant differences in medication compliance were found between the experimental group and the control group (p=0.109). Knowledge about schizophrenia and medications in the experimental group was significantly higher than that in control group (p<0.001). Within group comparison revealed that the incidence of adverse drug reactions in experimental group and control group significantly decreased. (p<0.001 และ p=0.002, respectively) Conclusion: Pharmaceutical care in outpatients with schizophrenia together with patient education, resolving drug related problems, distribution of handbook and telephone supervision improved patients’ knowledge about schizophrenia and medication, and reduced some types of drug related problems,
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcome Schizophr Res 1999; 35: S93-S100.
3. Tranulis C, Goff D, Henderson DC, Freudenreich O. Becoming adherent to antipsychotics: a qualita-tive study of treatment experienced schizophrenia patients. Psychiatr Serv 2011; 62: 888-92.
4. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 2013; 3: 200-18.
5. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: A systematic review of the literature. Can J Psychiatry 2002; 47: 833-43.
6. Llorca P-M. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008; 161: 235-47.
7. Montes JM, Maurino J, Diez T, Saiz-Ruiz J. Telephone-based nursing strategy to improve adherence to antipsychotic treatment in schizo-phrenia: A controlled trial. Int J Psychiatry Clin Prac 2010; 14: 274-81.
8. O'Donnell C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, et al. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ 2003; 327: 1-4.
9. World Health Organization. Adherence to long-term therapies. evidence for action. Geneva: World Health Organization. World Health Organization; 2003.
10. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
11. Sharif F, Shaygan M, Mani A. Effect of a psycho-educational intervention for family members on caregiver burdens and psychiatric symptoms in patients with schizophrenia in Shiraz, Iran. BMC Psychiatry 2012; 12: 1-9.
12. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers; 1988.
13. Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack GW, Grabowski J, et al. Using a pharmacy-based intervention to improve antipsy-chotic adherence among patients with serious mental illness. Schizophr Bull 2011; 37: 727-36.
14. Putkhao S. Factors affecting medication compliance in schizophrenic patients [master thesis]. Chaing Mai: Chaingmai University; 1998.
15. Hanrinth R. Classification for drug related problems. Thai Journal of Pharmacy Practice 2009; 1: 84-96.
16. Baitaptim C. Lives after discharge of the schizophrenic patients of Srithanya hospital [master thesis]. Bangkok: Thammasat University; 2004.
17. Breier A, Schreiber JL, Dyer J, Pickar D. National institute of mental health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Arc Gen Psychiatry 1991; 48: 239-46.
18. Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry 2013; 13: 1-8.
19. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone and olanzapine-treated inpatients: metabolic out-comes after 1 year. J Clin Psychiatry 2002; 63: 425-33.
20. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-12.
21. Felker B, Yazel J, Short D. Mortality and medical comorbidity among psychiatric patients: a review. Psychiatr Serv 1996; 47: 1356-63.
22. Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry 2002; 63(Suppl 9): 5-11.
23. Beebe LH, Smith K, Crye C, Addonizio C, Strunk DJ, Martin W, et al. Telenursing intervention increases psychiatric medication adherence in schizophrenia outpatients. J Am Psychiatr Nurses Assoc 2008; 14: 217-24.
